Asset Details
Do you wish to reserve the book?
Bevacizumab in the treatment of idiopathic macular telangiectasia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Bevacizumab in the treatment of idiopathic macular telangiectasia
Do you wish to request the book?
Bevacizumab in the treatment of idiopathic macular telangiectasia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Bevacizumab in the treatment of idiopathic macular telangiectasia
2008
Overview
Background
To describe functional and morphological long-term follow-up results in patients with idiopathic macular telangiectasia (IMT) treated with intravitreal bevacizumab.
Methods
Retrospective case series of three consecutive male patients with IMT who were treated with intravitreal bevacizumab injections. Best corrected visual acuity (BCVA) as well as fluorescein angiography (FA) and optical coherence tomography (OCT) were monitored over the period of up to 12 months.
Results
Single intravitreal bevacizumab injection resulted in a marked increase in BCVA from 20/50 to 20/20 in the patient with type 1 (aneurysmal) IMT during the first 4 weeks. Late-phase leakage on FA and cystoid macular oedema on OCT decreased significantly. This was sustained over the whole follow-up period of 12 months. In contrast, in the two patients with type 2 (perifoveal) IMT, leakage on FA decreased likewise, but this was not accompanied by an increase in BCVA despite triple injections. Small cystic changes seen on OCT remained unchanged.
Conclusion
Patients with type 1 IMT with pronounced macular oedema on OCT may benefit from intravitreal bevacizumab injections, showing functional as well as morphological improvement, while patients with type 2 IMT with minimal cystic changes on OCT do not show functional improvement despite repeated injections.
Publisher
Springer-Verlag,Springer Nature B.V
Subject
Angiogenesis Inhibitors - therapeutic use
/ Antibodies, Monoclonal - therapeutic use
/ Antibodies, Monoclonal, Humanized
/ Humans
/ Macular Edema - drug therapy
/ Macular Edema - physiopathology
/ Male
/ Medicine
/ Retinal Diseases - drug therapy
/ Retinal Diseases - physiopathology
/ Retinal Vessels - drug effects
/ Telangiectasis - drug therapy
/ Telangiectasis - physiopathology
/ Tomography, Optical Coherence
/ Vascular Endothelial Growth Factor A - antagonists & inhibitors
